Enanta Posts $23.7M Q4 Loss, Cuts Workforce by a Third, Cash Through Fiscal 2029
ENTA is trading near its 52-week low of $10.05 (3.6% above the low).
Summary
Enanta reported a $23.7M fiscal Q4 loss on $12.9M of royalty revenue and disclosed a roughly one-third workforce cut, with $194.5M in cash funding operations into fiscal 2029. Zelicapavir pediatric topline is expected in 1Q 2027.
Key Events · Earnings and Guidance · ENTA
-
Fiscal Q4 Loss Widens to $23.7M
Net loss was $23.7M, or $0.81 per diluted share, on revenue of $12.9M versus $18.7M ($0.87) on $15.1M a year earlier. Full-year net loss was $68.2M, or $2.35 per share, versus $81.9M ($3.84) in fiscal 2025.
-
Workforce Cut by Roughly One-Third
A September 2026 strategic review led to targeted workforce reductions of approximately one-third of employees, focusing resources on priority programs and extending financial flexibility.
-
Cash Runway Into Fiscal 2029
Cash, cash equivalents and marketable securities totaled $194.5M at September 30, 2026, which the company says funds operations into fiscal 2029 alongside its retained royalty revenue.
-
Immunology Timelines Slip Into 2027
EDP-978 Phase 1 topline data is now expected in 1Q 2027, and the EDP-903 STAT6 IND is now targeted for 2Q 2027 due to a drug manufacturing delay. EPS-5336 was selected as the MRGPRX2 development candidate with an IND targeted for 4Q 2027.
Analysis · ENTA · Life Sciences
The balance sheet is the story here: $194.5M in cash and securities, plus retained royalties, funds operations into fiscal 2029. That runway explains the September move to cut roughly one-third of the workforce, and it also frames the two immunology milestones pushed into 2027 — EDP-978 Phase 1 data and the EDP-903 IND, the latter now set for 2Q 2027 on a manufacturing delay. For the quarter, Enanta posted a $23.7M loss and a $68.2M full-year loss. Revenue remains entirely AbbVie's MAVYRET royalty stream, which fell to $12.9M from $15.1M a year ago, and 54.5% of that cash royalty goes to OMERS through 2032. Near-term value hinges on zelicapavir: LOTUS pediatric topline is due 1Q 2027 and RESOLVE Phase 2b data in 2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $10.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $310.8M. The 52-week trading range was $10.05 to $17.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.